Breast cancer trial shows signs of hope for patients

Getty Images  Canopy

Getty Images Canopy

A study looked at women in the "mid-risk" category where the benefits of chemo are uncertain.

Researchers were keen to stress that more trials on greater numbers of patients will need to be carried out before the therapy could come into wider use.

The women enrolled in the study were assigned to treatment groups based on their genetic testing score, to examine if chemo plus hormone therapy was beneficial when compared to what has become the standard treatment for this form of breast cancer - hormone therapy alone.

For Litton, the new study will make a tremendous difference in breast cancer treatment for many women.

The breast cancer study focused on cases where chemo's value increasingly is in doubt: women with early-stage disease that has not spread to lymph nodes, is hormone-positive (meaning its growth is fueled by estrogen or progesterone) and is not the type that the drug Herceptin targets. The study observed a potential chemotherapy benefit in younger women (≤50 years) with an RS of 16-25, while RS 0 to 15 had good prognosis with endocrine therapy. The results showed there might be a small benefit from chemotherapy.

Across the European Union, we have seen positive results for breast cancer care as more women are being diagnosed and treated earlier, leading to higher survival rates.

Doctors in the U.S. combined two different forms of immunotherapy after conventional hormone treatments and chemotherapy failed.

It was first issued in 1998 and has been reissued multiple times since, and has raised more than $86 million for breast cancer research.

Judy Perkins had been given three months to live, but two years later there is no sign of cancer in her body.

Arsenal Set to Sign Yacine Adli
Arsenal must be eager to avoid a repeat of that situation after inserting a break in new head coach Unai Emery's contract. He's one of the longest-serving players in the first team. "If there is a structure, Aaron Ramsey could be that guy".

"I have definitely hit the jackpot", said Perkins, a retired engineer from Port St. Lucie, Fla. "Now we know there's no need to give chemotherapy to those patients anymore", Mitchell said.

More than 20,000 women in the United Kingdom are diagnosed with hormone-receptor positive, HER2-negative, node-negative breast cancer annually.

The study published on Sunday, on which early-stage breast cancer patients can forgo chemo, is by far the most impactful so far.

Peter Johnson, Professor of Medical Oncology at Southampton General Hospital, said: "This is another piece of evidence confirming that some cancers are recognisable by the body's immune system and that if this can be stimulated in the right way, even cancers that have spread to different parts of the body may be treatable".

Researchers at the National Cancer Institute have put a patient with metastatic breast cancer into complete remission by using a new approach to immunotherapy. "I had a bucket-list of things I needed to do before the end, like going to the Grand Canyon", she added.

The success with Perkins' breast cancer follows reports of similar responses in patients who had advanced-stage cancers of the bile duct, colon and cervix.

Dr. Raymond says the study proves that chemo will hurt more than help women with low risk scores who are over 50.

Harold Burstein, a breast cancer specialist at Dana-Farber Cancer Institute, said that in some ways the debate over de-escalation misses a larger issue. But they tend to work best on cancers that are influenced by environmental factors and are driven by lots of mutated genes.

Latest News